Institutional investors purchased a net $1.2 thousand shares of NVGN during the quarter ended June 2017. This may signal that the smart money is gaining interest in this company as the 1.57% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
MORGAN STANLEY & CO. LLC Bought 3.2 Thousand shares of Kazia Therapeutics Ltd